Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone ...

Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated.

Non-Hodgkin lymphoma outcomes are linked to hemoglobin, LDH, ECOG scores, and disease stage, with extranodal cases needing more research. Extranodal NHL in head and neck regions is under-researched, ...

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...

Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

Liso-cel achieved a 95.5% overall response rate and a 62.1% complete response rate in MZL patients after at least two prior therapies. The two-year overall survival rate for patients treated with liso ...

Hematologists and rheumatologists may be able to adopt a more aggressive approach for managing low-grade marginal lymphoma in Sjögren disease, particularly mucosa-associated lymphoid tissue (MALT) ...